Adma Biologics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
ADMA Biologics has scheduled its 2026 Annual Meeting of Stockholders for June 2, 2026, to address director elections, auditor ratification, and executive compensation.
NASDAQ
ADMA Biologics, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
DEF: ADMA Biologics Announces 2025 Annual Meeting of Stockholders and Executive Compensation Details
ADMA Biologics has scheduled its 2025 annual meeting of stockholders for June 4, 2025, and released details regarding director nominations, executive compensation, and corporate governance.
NASDAQ
ADMA Biologics has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.
NASDAQ
ADMA Biologics will hold its annual stockholders meeting virtually on June 4, 2024, to vote on director elections and auditor ratification.